动物造模,孤独症模型,药效评价 zi-bio 2024-10-07 759

　　Objective: To explore the improvement effect of sulindac on the behavior of autism model rats.

　　Method: After 12.5 days of pregnancy, a rat model of autism was prepared by one-time intraperitoneal injection of sodium valproate (VPA). For the group treated with sulindac, rats were orally administered 20 mg/kg of sulindac daily after VPA injection until weaning. Divide newborn mice into four groups: control group, VPA treatment group, sulindac treatment group, and VPA combined with sulindac treatment group. 35 days after birth, social interaction behavior testing and open box anxiety like behavior testing were performed on young mice, and brain tissue proteins were isolated and extracted for Western blot analysis of key proteins in the Wnt signaling pathway β- Catenin and Gsk3 β Expression situation.

　　Result: A rat model of autism was successfully prepared. Compared with the control group, the VPA treatment group showed a decrease in social interaction ability, increased activity time in the central area, and decreased standing frequency, which is consistent with the behavioral characteristics of autism; There were no significant behavioral changes in the group treated with sulindac alone; However, the combined treatment with sulindac can significantly improve the behavioral symptoms of autism caused by VPA treatment. Western blot results showed that compared with the control group, VPA treatment can enhance the frontal lobe, hippocampus, and cerebellar tissues in rats β- Catenin expression level and reduction of Gsk3 β 9th serine phosphorylation level; And the combined treatment with succinic acid can inhibit the above-mentioned brain tissue β- Catenin expression level and increase of Gsk3 β The 9th level of serine phosphorylation.

　　Conclusion: Sulindac can improve the pathological behavior of autism model rats, and the mechanism may be related to the inhibition of the Wnt signaling pathway in brain tissue.